Procurement Margin as Nitra's Moat

The real moat is shifting from payment rails to purchasing power. A healthcare card can win early adoption with rewards and software, but those economics are thin, because net card take is around 1 percent and rewards are expensive. If Nitra becomes the place where clinics choose suppliers, create purchase orders, and route more supply spend through its marketplace, it can add rebates, better pricing, and marketplace margin on top of interchange.

• Nitra already frames procurement as the control point. Its roadmap includes demand forecasting, vendor comparison, substitute suggestions, order consolidation, and purchase order creation, which moves it from tracking spend after the fact to shaping what gets bought in the first place.
  1 sacra
• That matters because Nitra is currently monetized mostly like a card company. It processed over $1B in annualized purchase volume in Q4 2025 and reached $34M in annualized revenue in 2025, with most revenue tied to interchange, while software fees are often waived to drive primary card usage.
  1 sacra
• The closest comparison is BILL on the AP side versus Premier and Vizient on the healthcare supply side. BILL shows how AP, cards, and procurement can be bundled in one workflow, while Premier and Vizient show that aggregated healthcare purchasing can produce real pricing leverage and supplier economics.
  4 bill 5 premierinc 6 premierinc

The next phase is a move from spend management into healthcare purchasing infrastructure. If Nitra keeps embedding into clinic workflows and captures more supply ordering, procurement margin can make revenue less dependent on card take rates and turn a useful finance product into a harder to displace operating system for independent practices.